



## New Insights to Cancer Therapy Resistance

Guest Editor:

### Dr. Sebastian Oeck

West German Cancer Center,  
Department of Medical Oncology,  
University Hospital Essen,  
University of Duisburg-Essen,  
45147 Essen, Germany

Deadline for manuscript  
submissions:

**closed (29 February 2024)**

### Message from the Guest Editor

Dear Colleagues,

In recent decades, considerable advances have been made in understanding tumor-driving mechanisms, which have fueled the development of novel therapeutic approaches benefitting many patients. The major progress is represented by the further development of immunotherapy and targeted therapy with small molecules, e.g., KRAS<sup>G12C</sup>-specific inhibitors. Despite this considerable progress, cancer is an evolving disease, and resistance develops almost immediately and is found in clinics.

The current Special Issue addresses the emerging questions of how these forms of resistance occur and reveal the underlying mechanisms. The collation of more detailed knowledge obtained from experts of different cancer research fields addressing the relationships of molecular mechanisms and resistances occurring in clinics offers a great opportunity to promote an improved understanding and the development of resistance-overcoming approaches.

Dr. Sebastian Oeck  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)